CD274 and neoplasm: The Wistuba lab recently reviewed multiplex staining and DIA platforms, concluding with their utility and advantages for translational research and clinical applications [36], and a recent systematic review and meta-analysis of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade concluded that mIHC has improved diagnostic performance as compared with conventional PD-L1 IHC, tumor mutational burden, and gene expression profiling [37].